Intensified ChlVPP/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphoma

Research output: Contribution to journalArticle

Abstract

We present feasibility, toxicity and efficacy results of an intensified six-cycle ChlVPP/ABVVP regimen in advanced Hodgkin lymphoma (HL). From February 2004 to August 2007, 82 consecutive eligible patients were enrolled. According to the Hasenclever index, 64 patients (78%) were considered at low risk, 15 (18%) at intermediate and 3 (4%) at high risk. The most relevant toxicity was haematological: grade 3-4 neutropenia occurred in 32% of patients, grade 3-4 anaemia in 26% of patients. Severe infections and febrile neutropenia were observed in 8% of patients. With a median follow-up of 35 months (range 12-55), the three-year freedom from treatment failure (FFTF) and overall survival (OS) were 75% (95% CI 65%-86%) and 94% (95% CI 87%-99%), respectively. The intensified ChlVPP/ABVVP regimen in advanced HL is effective, does not seem to differ from standard regimens in terms of FFTF and OS and showed a favourable toxicity profile.

Original languageEnglish
Article number184
Journalecancermedicalscience
Volume4
Issue number1
DOIs
Publication statusPublished - Sep 8 2010

Fingerprint

Hodgkin Disease
Drug Therapy
Treatment Failure
Febrile Neutropenia
Survival
Neutropenia
Anemia
pegfilgrastim
Infection

Keywords

  • ChlVPP/ABVVP
  • Hodgkin lymphoma
  • Intensified regimen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{0ba1a9e9a9694ce4b218a5c7a01acad7,
title = "Intensified ChlVPP/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphoma",
abstract = "We present feasibility, toxicity and efficacy results of an intensified six-cycle ChlVPP/ABVVP regimen in advanced Hodgkin lymphoma (HL). From February 2004 to August 2007, 82 consecutive eligible patients were enrolled. According to the Hasenclever index, 64 patients (78{\%}) were considered at low risk, 15 (18{\%}) at intermediate and 3 (4{\%}) at high risk. The most relevant toxicity was haematological: grade 3-4 neutropenia occurred in 32{\%} of patients, grade 3-4 anaemia in 26{\%} of patients. Severe infections and febrile neutropenia were observed in 8{\%} of patients. With a median follow-up of 35 months (range 12-55), the three-year freedom from treatment failure (FFTF) and overall survival (OS) were 75{\%} (95{\%} CI 65{\%}-86{\%}) and 94{\%} (95{\%} CI 87{\%}-99{\%}), respectively. The intensified ChlVPP/ABVVP regimen in advanced HL is effective, does not seem to differ from standard regimens in terms of FFTF and OS and showed a favourable toxicity profile.",
keywords = "ChlVPP/ABVVP, Hodgkin lymphoma, Intensified regimen",
author = "E. Cocorocchio and A. Vanazzi and S. Bassi and F. Peccatori and P. Antoniotti and F. Gigli and L. Travaini and G. Piperno and G. Pruneri and L. Preda and R. Biffi and E. Botteri and M. Negri and G. Martinelli",
year = "2010",
month = "9",
day = "8",
doi = "10.3332/ecancer.2010.184",
language = "English",
volume = "4",
journal = "ecancermedicalscience",
issn = "1754-6605",
publisher = "Cancer Intellilgence",
number = "1",

}

TY - JOUR

T1 - Intensified ChlVPP/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphoma

AU - Cocorocchio, E.

AU - Vanazzi, A.

AU - Bassi, S.

AU - Peccatori, F.

AU - Antoniotti, P.

AU - Gigli, F.

AU - Travaini, L.

AU - Piperno, G.

AU - Pruneri, G.

AU - Preda, L.

AU - Biffi, R.

AU - Botteri, E.

AU - Negri, M.

AU - Martinelli, G.

PY - 2010/9/8

Y1 - 2010/9/8

N2 - We present feasibility, toxicity and efficacy results of an intensified six-cycle ChlVPP/ABVVP regimen in advanced Hodgkin lymphoma (HL). From February 2004 to August 2007, 82 consecutive eligible patients were enrolled. According to the Hasenclever index, 64 patients (78%) were considered at low risk, 15 (18%) at intermediate and 3 (4%) at high risk. The most relevant toxicity was haematological: grade 3-4 neutropenia occurred in 32% of patients, grade 3-4 anaemia in 26% of patients. Severe infections and febrile neutropenia were observed in 8% of patients. With a median follow-up of 35 months (range 12-55), the three-year freedom from treatment failure (FFTF) and overall survival (OS) were 75% (95% CI 65%-86%) and 94% (95% CI 87%-99%), respectively. The intensified ChlVPP/ABVVP regimen in advanced HL is effective, does not seem to differ from standard regimens in terms of FFTF and OS and showed a favourable toxicity profile.

AB - We present feasibility, toxicity and efficacy results of an intensified six-cycle ChlVPP/ABVVP regimen in advanced Hodgkin lymphoma (HL). From February 2004 to August 2007, 82 consecutive eligible patients were enrolled. According to the Hasenclever index, 64 patients (78%) were considered at low risk, 15 (18%) at intermediate and 3 (4%) at high risk. The most relevant toxicity was haematological: grade 3-4 neutropenia occurred in 32% of patients, grade 3-4 anaemia in 26% of patients. Severe infections and febrile neutropenia were observed in 8% of patients. With a median follow-up of 35 months (range 12-55), the three-year freedom from treatment failure (FFTF) and overall survival (OS) were 75% (95% CI 65%-86%) and 94% (95% CI 87%-99%), respectively. The intensified ChlVPP/ABVVP regimen in advanced HL is effective, does not seem to differ from standard regimens in terms of FFTF and OS and showed a favourable toxicity profile.

KW - ChlVPP/ABVVP

KW - Hodgkin lymphoma

KW - Intensified regimen

UR - http://www.scopus.com/inward/record.url?scp=80054731713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054731713&partnerID=8YFLogxK

U2 - 10.3332/ecancer.2010.184

DO - 10.3332/ecancer.2010.184

M3 - Article

C2 - 22276036

AN - SCOPUS:80054731713

VL - 4

JO - ecancermedicalscience

JF - ecancermedicalscience

SN - 1754-6605

IS - 1

M1 - 184

ER -